Non-invasive assessment of hepatic steatosis by ultrasound-derived fat fraction in individuals at high-risk for metabolic dysfunction-associated steatotic liver disease.
NAFLD
NASH
abdominal ultrasound
controlled attenuation parameter
fatty liver
imaging biomarkers
Journal
Diabetes/metabolism research and reviews
ISSN: 1520-7560
Titre abrégé: Diabetes Metab Res Rev
Pays: England
ID NLM: 100883450
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
05
02
2024
received:
05
12
2023
accepted:
15
02
2024
medline:
10
3
2024
pubmed:
10
3
2024
entrez:
10
3
2024
Statut:
ppublish
Résumé
Given the increasing number of individuals developing metabolic dysfunction-associated steatotic liver disease (MASLD) and the low rate of those with progressive liver disease, there is a pressing need to conceive affordable biomarkers to assess MASLD in general population settings. Herein, we aimed to investigate the performance of the ultrasound-derived fat fraction (UDFF) for hepatic steatosis in high-risk individuals. A total of 302 Europeans with obesity, type 2 diabetes, or a clinical history of hepatic steatosis were included in the analyses. Clinical, laboratory, and imaging data were collected using standardized procedures during a single screening visit in Rome, Italy. Hepatic steatosis was defined by controlled attenuation parameter (CAP) or ultrasound-based Hamaguchi's score. UDFF performance for hepatic steatosis was estimated by the area under the receiver operating characteristic curve (AUC). Overall, median (IQR) UDFF was 12% (7-20). UDFF was positively correlated with CAP (ρ = 0.73, p < 0.0001) and Hamaguchi's score (ρ = 0.79, p < 0.0001). Independent predictors of UDFF were circulating triglycerides, alanine aminotransferase (ALT), and ultrasound-measured visceral adipose tissue (VAT). UDFF AUC was 0.89 (0.85-0.93) and 0.92 (0.88-0.95) for CAP- and ultrasound-diagnosed hepatic steatosis, respectively. UDFF AUC for hepatic steatosis was higher than those of fatty liver index (FLI), hepatic steatosis index (HSI), CAP-score (CAPS), and ALT (p < 0.0001). Lower age, ALT, and VAT were associated with discordance between UDFF and ultrasound. UDFF may be a simple and accurate imaging biomarker to assess hepatic steatosis and monitor changes in hepatic fat content over time or in response to therapeutic interventions beyond clinical trials.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3787Subventions
Organisme : Ricerca Finalizzata Ministero della Salute
ID : RF-2021-12374481
Organisme : AstraZeneca Agreement for Research
Organisme : Progetti di Ricerca di Rilevante Interesse Nazionale Ministero dell'Università e della Ricerca
ID : PRIN 2022BZFFFY
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. https://doi.org/10.1097/HEP.0000000000000520
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556. https://doi.org/10.1016/j.jhep.2023.06.003
Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202-209. https://doi.org/10.1016/j.jhep.2020.03.039
Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. https://doi.org/10.1097/hep.0000000000000004
Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537-2564. https://doi.org/10.1016/j.cell.2021.04.015
Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, Diseases AAftSoL. Liver biopsy. Hepatology. 2009;49(3):1017-1044. https://doi.org/10.1002/hep.22742
Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-478. https://doi.org/10.1038/s41575-018-0014-9
Ferraioli G, Berzigotti A, Barr RG, et al. Quantification of liver fat content with ultrasound: a WFUMB position paper. Ultrasound Med Biol. 2021;47(10):2803-2820. https://doi.org/10.1016/j.ultrasmedbio.2021.06.002
Dongiovanni P, Stender S, Pietrelli A, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med. 2018;283(4):356-370. https://doi.org/10.1111/joim.12719
Harrison SA, Loomba R, Dubourg J, Ratziu V, Noureddin M. Clinical trial landscape in NASH. Clin Gastroenterol Hepatol. 2023;21(8):2001-2014. https://doi.org/10.1016/j.cgh.2023.03.041
Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018;68(2):763-772. https://doi.org/10.1002/hep.29797
Noureddin M, Lam J, Peterson MR, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;58(6):1930-1940. https://doi.org/10.1002/hep.26455
(EASL) EAftSotL, (EASD) EAftSoD, (EASO) EAftSoO. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402.
Ferraioli G, Kumar V, Ozturk A, Nam K, de Korte CL, Barr RG. US attenuation for liver fat quantification: an AIUM-RSNA QIBA pulse-echo quantitative ultrasound initiative. Radiology. 2022;302(3):495-506. https://doi.org/10.1148/radiol.210736
Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. https://doi.org/10.1016/j.jhep.2016.12.022
Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717-1730. https://doi.org/10.1053/j.gastro.2019.01.042
Petroff D, Blank V, Newsome PN, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(3):185-198. https://doi.org/10.1016/s2468-1253(20)30357-5
Kozłowska-Petriczko K, Wunsch E, Petriczko J, Syn WK, Milkiewicz P. Diagnostic accuracy of non-imaging and ultrasound-based assessment of hepatic steatosis using controlled attenuation parameter (CAP) as reference. J Clin Med. 2021;10(7):1507. https://doi.org/10.3390/jcm10071507
Berzigotti A, Tsochatzis E, Boursier J, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659-689. https://doi.org/10.1016/j.jhep.2021.05.025
Labyed Y, Milkowski A. Novel method for ultrasound-derived fat fraction using an integrated phantom. J Ultrasound Med. 2020;39(12):2427-2438. https://doi.org/10.1002/jum.15364
DillmanThapaliya JRS, Tkach JA, Trout AT. Quantification of hepatic steatosis by ultrasound: prospective comparison with MRI proton density fat fraction as reference standard. AJR Am J Roentgenol. 2022;219(5):784-791. https://doi.org/10.2214/ajr.22.27878
De Robertis R, Spoto F, Autelitano D, et al. Ultrasound-derived fat fraction for detection of hepatic steatosis and quantification of liver fat content. Radiol Med. 2023;128(10):1174-1180. https://doi.org/10.1007/s11547-023-01693-8
Zalcman M, Barth RA, Rubesova E. Real-time ultrasound-derived fat fraction in pediatric population: feasibility validation with MR-PDFF. Pediatr Radiol. 2023;53(12):2466-2475. https://doi.org/10.1007/s00247-023-05752-0
Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15-S33. https://doi.org/10.2337/dc21-s002
Unger T, Borghi C, Charchar F, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334-1357. https://doi.org/10.1161/hypertensionaha.120.15026
Expert Panel on Detection Ea, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486-2497. https://doi.org/10.1001/jama.285.19.2486
Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-4806. https://doi.org/10.1093/eurheartj/ehab551
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. https://doi.org/10.1007/bf00280883
Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6(1):33. https://doi.org/10.1186/1471-230x-6-33
Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503-508. https://doi.org/10.1016/j.dld.2009.08.002
Bianco C, Pelusi S, Margarita S, et al. Predictors of Controlled Attenuation Parameter in Metabolic Dysfunction. United European Gastroenterol J.; 2023.
Liver EAfSo, Higado ALpeEd. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264.
Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835-847. https://doi.org/10.1016/j.jhep.2008.02.008
Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(1):156-163.e152. https://doi.org/10.1016/j.cgh.2018.04.043
Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102(12):2708-2715. https://doi.org/10.1111/j.1572-0241.2007.01526.x
Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-750. https://doi.org/10.1053/gast.2002.35354
Cuatrecasas G, de Cabo F, Coves MJ, et al. Ultrasound measures of abdominal fat layers correlate with metabolic syndrome features in patients with obesity. Obes Sci Pract. 2020;6(6):660-667. https://doi.org/10.1002/osp4.453